RESUMO
Biomarker profiles of acute rejection in liver transplant recipients could enhance the diagnosis and management of recipients. Our aim was to identify diagnostic proteoform signatures of acute rejection in circulating immune cells, using an emergent "top-down" proteomics methodology. We prepared differentially processed and cryopreserved cell lysates from 26 nonviral liver transplant recipients by molecular weight-based fractionation and analyzed them by mass spectrometry of whole proteins in three steps: (i) Nanocapillary liquid chromatography coupled with high-resolution tandem mass spectrometry; (ii) database searching to identify and characterize intact proteoforms; (iii) data processing through a hierarchical linear model matching the study design to quantify proteoform fold changes in patients with rejection versus normal liver function versus acute dysfunction without rejection. Differentially expressed proteoforms were seen in patients with rejection versus normal and nonspecific controls, most evidently in the cell preparations stored in traditional serum-rich media. Mapping analysis of these proteins back to genes through gene ontology and pathway analysis tools revealed multiple signaling pathways, including inflammation mediated by cytokines and chemokines. Larger studies are needed to validate these novel rejection signatures and test their predictive value for use in clinical management.
Assuntos
Biomarcadores/sangue , Rejeição de Enxerto/diagnóstico , Leucócitos Mononucleares/metabolismo , Transplante de Fígado/efeitos adversos , Proteoma/análise , Bases de Dados de Proteínas , Feminino , Rejeição de Enxerto/sangue , Rejeição de Enxerto/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Isoformas de Proteínas , ProteômicaRESUMO
A topic of current interest in islet transplantation is the selection of an optimal site for long-term graft survival since the intrahepatic site may be characterized by long-term failure. Additionally, the use of immunosuppressive agents such as prednisone may adversely affect long-term graft function. In this study, we examined the long-term outcome of intrahepatic canine islet autografts and compared this with results obtained in animals treated with a short-term course of steroids or steroids plus insulin. Islets were isolated using the automated method and were purified on discontinuous Euro-Collins Ficoll gradients (densities: 1.108, 1.096, 1.037). Prednisone-treated dogs were hyperglycemic during treatment but returned to normoglycemia after steroid withdrawal. Control and insulin-treated animals were normoglycemic following autotransplant, with no difference in plasma glucose levels between controls and the insulin-treated animals. All control dogs became diabetic at 11, 14, 17, and 19 months following islet autograft. Prednisone-treated dogs had more rapid onset of diabetes at 7, 11, and 12 months following ITx. Prednisone-treated dogs given insulin became hyperglycemic at 10, 14, 18, and 19 months post ITx. Graft failure was preceded by a decline in IVGTT Kg values and diminished insulin secretion. At the time of graft failure islets showed no lymphocytic infiltration and islets stained positive for glucagon but few insulin-containing cells were seen. Thus, even when an initially adequate B cell mass was transplanted, the intrahepatic site was characterized by long-term canine autograft failure. A short course of prednisone accelerated the time to graft failure and insulin treatment reversed this acceleration.
Assuntos
Rejeição de Enxerto/induzido quimicamente , Transplante das Ilhotas Pancreáticas/imunologia , Prednisona/efeitos adversos , Animais , Glicemia/análise , Doença Crônica , Diabetes Mellitus Experimental/imunologia , Diabetes Mellitus Experimental/cirurgia , Cães , Feminino , Rejeição de Enxerto/imunologia , Insulina/administração & dosagem , Insulina/metabolismo , Secreção de Insulina , Transplante das Ilhotas Pancreáticas/patologia , Fígado/imunologia , Fígado/cirurgia , Masculino , Prednisona/administração & dosagem , Transplante AutólogoRESUMO
It has been postulated that the resident "passenger" leukocytes of hematolymphoid origin that migrate from whole organ grafts and subsequently establish systemic chimerism are essential for graft acceptance and the induction of donor-specific nonreactivity. This phenomenon was augmented by infusing 3 x 10(8) unmodified donor bone-marrow cells into 40 patients at the time of organ transplantation. Fifteen of the first 18 analyzable patients had sequential immunological evaluation over postoperative intervals of 5 to 17 months, (which included 7 kidney (two with islets), 7 liver (one with islets), and one heart recipient). The evolution of changes was compared with that in 16 kidney and liver nonmarrow controls followed for 4 to 5 months. The generic immune reactivity of peripheral blood mononuclear cells (PBMC) was determined by their proliferative responses to mitogens (PHA, ConA). Alloreactivity was measured by the recipient mixed lymphocyte reaction (MLR) to donor and HLA-mismatched third-party panel cells. Based on all 3 tests, the recipients were classified as donor-specific hyporeactive, intermediate, and responsive; patients who were globally suppressed made up a fourth category. Eight (53%) of the 15 marrow-treated recipients exhibited progressive modulation of donor-specific reactivity (3 hyporeactive and 5 intermediate) while 7 remained antidonor-responsive. In the nonmarrow controls, 2 (12.5%) of the 16 patients showed donor-specific hyporeactivity, 10 (62.5%) were reactive, and 4 (25%) studied during a CMV infection had global suppression of responsiveness to all stimuli.
Assuntos
Transplante de Medula Óssea/imunologia , Sobrevivência de Enxerto/imunologia , Isoanticorpos/imunologia , Leucócitos Mononucleares/imunologia , Transplante de Órgãos , Adulto , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Citotoxicidade Imunológica , Seguimentos , Humanos , Terapia de Imunossupressão , Isoanticorpos/biossíntese , Leucócitos Mononucleares/patologia , Linfócitos/imunologia , Linfócitos/patologiaRESUMO
BACKGROUND: Tacrolimus (Tac) and mycophenolate mofetil (MMF) are newly approved immunosuppressive agents. However, the safety and efficacy of the combination of MMF and Tac in primary liver transplantation has not been determined. METHODS: An Institutional Review Board-approved, open-label prospective randomized protocol was initiated to study the efficacy and toxicity of Tac and steroids (double-drug therapy) versus Tac, steroids, and MMF (triple-drug therapy) in primary adult liver transplant recipients. Both groups of patients began on the same doses of Tac and steroids. Patients randomized to triple-drug therapy also received 1 g of MMF twice a day. RESULTS: Between August 1995 and January 1997, 200 patients were enrolled, 99 in double-drug therapy and 101 in triple-drug therapy. All patients were followed until May 1997, with a mean follow-up of 12.7 months. During the study period, 28 of 99 patients in double-drug therapy received MMF to control ongoing acute rejection, nephrotoxicity, and/or neurotoxicity. On the other hand, 61 patients in triple-drug therapy discontinued MMF for infection, myelosuppression, and/or gastrointestinal disturbances. By an "intention-to-treat analysis," the actuarial 1-year patient survival rate was 85.1% in double-drug therapy and 83.1% in triple-drug therapy (P=0.77). The actuarial 1-year graft survival rate was 80.2% for double-drug therapy and 79.2% for triple-drug therapy (P=0.77). Forty-one patients (41.4%) in double-drug therapy and 32 (31.7%) in triple-drug therapy had at least one episode of rejection, but this was not statistically significant (P=0.15). The mean maintenance dose of corticosteroids was slightly lower in triple-drug compared with double-drug therapy. CONCLUSION: Patient and graft survival rates were similar in both groups. There was a trend to a lower incidence of rejection, reduced nephrotoxicity, and a lesser amount of maintenance corticosteroids in triple-drug therapy compared with double-drug therapy.
Assuntos
Imunossupressores/uso terapêutico , Transplante de Fígado/imunologia , Ácido Micofenólico/análogos & derivados , Tacrolimo/uso terapêutico , Adulto , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Humanos , Masculino , Ácido Micofenólico/uso terapêutico , Estudos Prospectivos , Taxa de SobrevidaRESUMO
We have employed recently developed techniques in T-cell culturing to study the nature and function of infiltrating hepatic allograft T cells. Using the rationale that intragraft T cells are activated during cell mediated damage to the allograft, we were able to show that these cells would propagate and remain functionally active in the presence of the T-cell growth factor, IL-2. In several instances, phenotypic analysis of cells grown in this manner was very similar to that found within the graft. Both proliferative and cytotoxic responses could be detected from the cultured cell lines. The majority of the proliferative responses were donor-directed and immunogenetic analysis could define donor-directed HLA reactivity, to either class I or class II antigens, or both. Monoclonal anti-HLA antibodies inhibition profiles verified the apparent HLA reactivity. In a smaller percentage of cases, only IL-2 responsiveness could be detected, and no HLA reactivity could be determined. Cytotoxicity could be detected against both class I and class II antigens, however, those cells which demonstrated a greater magnitude of donor-directed cytotoxicity appeared to be directed against class I antigens. A significant correlation between donor-directed proliferation of biopsy cultured lymphocytes and cellular rejection was found. This model appears to be useful in delineating functions of the intragraft T-cell population during rejection.
Assuntos
Transplante de Fígado , Linfócitos T/fisiologia , Adolescente , Adulto , Anticorpos Monoclonais , Antígenos de Diferenciação de Linfócitos T , Antígenos de Superfície/imunologia , Biópsia , Células Cultivadas , Criança , Testes Imunológicos de Citotoxicidade/métodos , Feminino , Antígenos HLA/imunologia , Humanos , Interleucina-2/farmacologia , Fígado/citologia , Fígado/patologia , Ativação Linfocitária/efeitos dos fármacos , Complexo Principal de Histocompatibilidade , Masculino , Pessoa de Meia-Idade , Fenótipo , Doadores de Tecidos , Transplante HomólogoRESUMO
In dogs the most effective oral dose of FK 506 for prevention of renal homograft rejection was 1.5 mg/kg/day. With maximum credit allowed at 90 days, survival was increased to 61.0 +/- 33.6 (SD) days compared with 13.0 +/- 4.1 in untreated control animals. Higher doses were toxic. The smallest dose that was used (0.5 mg/kg/day) prolonged survival after renal transplantation to 33.7 +/- 23.9 (SD) days. When the small dose of FK 506 was combined with 5 mg/kg/day of cyclosporine and 5 mg of prednisone, five of six canine kidney recipients lived for 90 days. These results were degraded by omission of any of the constituent drugs or reduction by half of the triple drug doses. Thirteen of the dogs treated with various drug regimens lived for 90 days, after which time treatment was stopped; 10 of the dogs eventually rejected the grafts, but three had continued graft function for 6 months or longer and may be permanently tolerant. Moreover, in dogs when 1 mg/kg of intramuscular FK was given to 19 kidney and seven liver recipients for 3 days on postoperative days 1 to 3, 4 to 6, or 7 to 9, the animals survived subsequently for 11 to more than 160 days. All but four of the grafts were eventually rejected, but the prolonged effect of a short course of delayed therapy suggests the possibility of tolerance induction. In cynomolgus monkeys and baboons, FK as a single drug was found to be immunosuppressive after kidney transplantation. Correlation in the dogs and primates between immunosuppression, toxicity, and FK blood levels was not possible because of presently imperfect standardization of assay and monitoring techniques. FK had serious side effects in dogs, but not so obviously in monkeys and not at all in baboons.
Assuntos
Sobrevivência de Enxerto/efeitos dos fármacos , Imunossupressores/uso terapêutico , Transplante de Rim , Animais , Ciclosporinas/administração & dosagem , Cães , Sinergismo Farmacológico , Quimioterapia Combinada , Tolerância Imunológica/efeitos dos fármacos , Transplante de Fígado , Macaca fascicularis , Papio , Prednisona/administração & dosagem , Piridinas/administração & dosagem , Piridinas/efeitos adversos , Piridinas/uso terapêutico , Tacrolimo , Transplante HomólogoRESUMO
Lymphangiomatosis is a rare malformation of the lymphatic system that causes severe symptoms secondary to progressive growth into or close to vital structures. A case report of liver failure related to this space-occupying intrahepatic mechanism is taken as a starting point for a discussion of the problems of liver transplantation related to large hepatomegalies.
Assuntos
Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Linfangioma/cirurgia , Adulto , Feminino , Hepatectomia , Hepatomegalia/etiologia , Humanos , Fígado/patologia , Neoplasias Hepáticas/patologia , Linfangioma/patologiaRESUMO
Epstein-Barr virus encoded RNA's (EBER) are small RNA species found in cells latently infected by the virus. The physiological function of these molecules is currently a matter of speculation. Nonetheless, their presence in extremely high copy number has made it possible to reliably detect the Epstein-Barr virus by in-situ hybridization, in human tissues routinely fixed with formalin and embedded in paraffin. Such studies have enhanced our understanding of a number of hematologic malignancies, particularly Hodgkin's disease, angiocentric immunoproliferative lesions and angio-immunoblastic lymphadenopathy. In addition, sequential EBER in-situ hybridization studies on lymphoid tissues should enable oncologists to monitor the development of lymphoproliferative disorders occurring in the setting of organ transplantation, AIDS and hereditary immunodeficiencies.
Assuntos
Doenças Hematológicas/genética , Doenças Hematológicas/microbiologia , Infecções por Herpesviridae/genética , Infecções por Herpesviridae/microbiologia , Herpesvirus Humano 4/genética , Neoplasias/genética , Neoplasias/microbiologia , Proteínas de Ligação a RNA/genética , Proteínas Ribossômicas , Infecções Tumorais por Vírus/genética , Infecções Tumorais por Vírus/microbiologia , HumanosRESUMO
BACKGROUND: Although tacrolimus-based immunosuppression has made intestinal transplantation feasible, the risk of the requisite chronic high-dose treatment has inhibited the widespread use of these procedures. We have examined our 1990-1997 experience to determine whether immunomodulatory strategies to improve outlook could be added to drug treatment. STUDY DESIGN: Ninety-eight consecutive patients (59 children, 39 adults) with a panoply of indications received 104 allografts under tacrolimus-based immunosuppression: intestine only (n = 37); liver and intestine (n = 50); or multivisceral (n = 17). Of the last 42 patients, 20 received unmodified adjunct donor bone marrow cells; the other 22 were contemporaneous control patients. RESULTS: With a mean followup of 32 +/- 26 months (range, 1-86 months), 12 recipients (3 intestine only, 9 composite grafts) are alive with good nutrition beyond the 5-year milestone. Forty-seven (48%) of the total group survive bearing grafts that provide full (91%) or partial (9%) nutrition. Actuarial patient survival at 1 and 5 years (72% and 48%, respectively) was similar with isolated intestinal and composite graft recipients, but the loss rate of grafts from rejection was highest with intestine alone. The best results were in patients between 2 and 18 years of age (68% at 5 years). Adjunct bone marrow did not significantly affect the incidence of graft rejection, B-cell lymphoma, or the rate or severity of graft-versus-host disease. CONCLUSIONS: These results demonstrate that longterm rehabilitation similar to that with the other kinds of organ allografts is achievable with all three kinds of intestinal transplant procedures, that the morbidity and mortality is still too high for their widespread application, and that the liver is significantly but marginally protective of concomitantly engrafted intestine. Although none of the endpoints were markedly altered by donor leukocyte augmentation (and chimerism) with bone marrow, establishment of the safety of this adjunct procedure opens the way to further immune modulation strategies that can be added to the augmentation protocol.
Assuntos
Imunossupressores/uso terapêutico , Intestinos/transplante , Análise Atuarial , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/uso terapêutico , Adolescente , Adulto , Fatores Etários , Transplante de Medula Óssea , Criança , Pré-Escolar , Estudos de Viabilidade , Feminino , Seguimentos , Rejeição de Enxerto/etiologia , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/etiologia , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Incidência , Lactente , Transfusão de Leucócitos , Transplante de Fígado , Linfoma de Células B/etiologia , Masculino , Pessoa de Meia-Idade , Fenômenos Fisiológicos da Nutrição , Fatores de Risco , Segurança , Taxa de Sobrevida , Tacrolimo/administração & dosagem , Tacrolimo/efeitos adversos , Tacrolimo/uso terapêutico , Quimeras de Transplante , Imunologia de Transplantes , Transplante Homólogo , Resultado do TratamentoRESUMO
Epstein-Barr-virus-associated posttransplant lymphoproliferative disease ranges from transient lymphadenitis to aggressive lymphoma. This study characterizes an in vitro model to study the pathogenesis of this disease with a cell culture system. Five B-cell lines derived from posttransplant lymphoproliferative disease tissue were characterized with regard to immunophenotype, karyotype, molecular genetics, cytokine production, and growth regulation. All cell lines expressed CD19, CD21, CD22, CD43, and CD77, but not CD10 antigens. Immunoglobulin light chain restriction was seen in four of five cell lines, and cytogenetic abnormalities were demonstrable in three of the five. Cells proliferating in culture contained multiple Epstein-Barr virus episomes and showed lytic viral replication. All cell lines produced tumor necrosis factor-beta and interleukin-10 without evidence of autocrine growth regulatory loops involving these cytokines. No evidence of IL-1 alpha, IL-2, IL-4, IL-5 or IL-6 production was found by reverse transcriptase polymerase chain reaction. Adding 500 U IFN-alpha/ml to the culture medium resulted in 30% inhibition of [3H]thymidine incorporation.
Assuntos
Linfócitos B/metabolismo , Citocinas/biossíntese , Herpesvirus Humano 4 , Interferon-alfa/farmacologia , Transtornos Linfoproliferativos/virologia , Transplante de Órgãos/efeitos adversos , Adulto , Linfócitos B/imunologia , Linhagem Celular , Criança , Feminino , Rearranjo Gênico , Infecções por Herpesviridae/patologia , Herpesvirus Humano 4/crescimento & desenvolvimento , Humanos , Imunofenotipagem , Interleucina-10/biossíntese , Interleucinas/biossíntese , Cariotipagem , Transtornos Linfoproliferativos/genética , Transtornos Linfoproliferativos/imunologia , Linfotoxina-alfa/biossíntese , Masculino , Infecções Tumorais por Vírus/patologiaRESUMO
FK506 is the most potent immunosuppressive agent known. Its toxicity is substantial in dogs, minor in rats, and unknown in subhuman primates. In small doses that are nontoxic even in dogs, it can be used in synergistic combination with cyclosporine, steroids, and presumably in other drugs.
Assuntos
Rejeição de Enxerto/efeitos dos fármacos , Imunossupressores/uso terapêutico , Animais , Ciclosporinas/administração & dosagem , Cães , Avaliação Pré-Clínica de Medicamentos , Quimioterapia Combinada , Transplante de Coração , Imunossupressores/toxicidade , Nefropatias/induzido quimicamente , Transplante de Rim , Transplante de Fígado , Prednisona/administração & dosagem , Piridinas/administração & dosagem , Piridinas/uso terapêutico , Piridinas/toxicidade , Ratos , Ratos Endogâmicos ACI/imunologia , Ratos Endogâmicos BN/imunologia , Ratos Endogâmicos Lew/imunologia , Tacrolimo , Transplante Heterólogo , Transplante HomólogoRESUMO
A model of hepatic ischemia was developed in dogs using a pump-driven splanchnic-to-jugular vein bypass during crossclamping of the portal triad. An LD50 was established with three hours of ischemia. PGI2 given for one hour before the ischemic insult ameliorated the ischemic injury and increased survival.